Physician

John Mulvey, MD

According to 2025 Medicare claims, John Mulvey, MD (NPI: 1902863509) practices family practice in the Wilmington, DE-MD-NJ market, with the plurality of this provider's patient population coming from Cecil, MD. This provider's primary affiliated billing organization is JOHN R. MULVEY M.D., P.A. (NPI: 1093729493; TIN: 52-2131429) and primary practice location at 21921-5509.

Mulvey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 314 traditional Medicare patients, billed 2,110 HCPCS/CPT codes, and received $106,915 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 5,096 prescription claims across 330 beneficiaries totaling $603,873 in drug costs, led by Jardiance (Empagliflozin). DME data shows 233 claims. Open Payments data shows 56 records totaling $1,072. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $8,522 to $27,065.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	313	2,075	$111,113
2016	327	1,951	$107,852
2017	321	2,079	$116,768
2018	366	2,174	$116,977
2019	357	1,876	$103,617
2020	339	1,809	$93,434
2021	317	1,966	$120,890
2022	330	2,010	$132,306
2023	322	1,869	$112,992
2024	314	2,110	$106,915

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	225	4,262	$474,255
2016	237	4,511	$482,384
2017	260	4,499	$539,624
2018	264	4,575	$579,606
2019	272	4,328	$558,053
2020	261	4,120	$555,843
2021	262	4,425	$535,824
2022	294	4,486	$534,690
2023	320	4,765	$664,840
2024	330	5,096	$603,873

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	42	245	$5,173
2016	27	149	$2,771
2017	40	211	$4,069
2018	30	201	$7,828
2019	24	231	$14,527
2020	19	303	$19,337
2021	N/R	307	$33,958
2022	12	287	$33,855
2023	14	299	$26,746
2024	N/R	233	$32,613

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	198	198	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	254	449	$55
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	146	224	$39
96138	Administration of psychological or neuropsychological test by technician, first 30 minutes	134	139	$21
G0442	Annual alcohol misuse screening, 5 to 15 minutes	199	199	$19

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	50	3,470	$62,584
Farxiga	Dapagliflozin Propanediol	64	3,030	$53,995
Eliquis	Apixaban	42	2,700	$51,240
Rybelsus	Semaglutide	28	1,260	$38,398
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	38	1,320	$28,851

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	12	$9,166
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	29	$8,989
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	N/R	12	$3,948
A4624	Tracheal suction catheter, any type other than closed system, each	N	N/R	12	$2,930
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	12	$1,826

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$1,072	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Mulvey, MD?

Tedicare shows public-source Medicare data for John Mulvey, MD (NPI 1902863509), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Mulvey, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Mulvey, MD?

John Mulvey, MD is linked to JOHN R. MULVEY M.D., P.A. (billing NPI 1093729493) in the available physician profile data.

Does John Mulvey, MD have Open Payments data?

John Mulvey, MD has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.